Overview

Capecitabine and Oxaliplatin Plus Bevacizumab as Neoadjuvant Treatment for Untreated Unresectable Liver-only Metastases From Colorectal Cancer

Status:
Completed

Trial end date:
2015-02-01

Target enrollment:

Participant gender:

Summary

To evaluate the overall response rate of patients with previously untreated unresectable liver-only metastases from colorectal cancer treated with neoadjuvant capecitabine and oxaliplatin plus bevacizumab.

Phase:

Phase 2

Details

Lead Sponsor:

Royal Marsden NHS Foundation Trust

Collaborator:

Roche Pharma AG

Treatments:

Bevacizumab
Capecitabine
Oxaliplatin